Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Senti Biosciences ( (SNTI) ) has shared an announcement.
On April 27, 2026, Senti Biosciences Holdings, Inc. and its subsidiaries entered into a securities purchase agreement with an investor affiliated with major shareholder Celadon Partners SPV 24 for a private placement of up to $40 million in senior secured convertible notes, issued in two tranches and secured by first-priority liens on substantially all assets. The first $10 million tranche is tied to the recently completed holding company reorganization, while a potential second $30 million tranche depends on Celadon’s election and execution of definitive documents for a possible merger and contingent value right transaction linked to milestones for SENTI-202.
Proceeds from the notes are earmarked largely for general corporate purposes and to advance CMC activities and clinical trials for SENTI-202, with Senti agreeing to issuance limitations, a 3% fee to Celadon, and a shareholder vote by August 31, 2026 on removing Nasdaq-related issuance caps. The notes, which carry no interest absent default, feature a six-month maturity with a 200% cash payback if not converted or exchanged, full-ratchet anti-dilution protection, and extensive default redemption rights, while related registration and voting agreements are designed to facilitate resale of underlying shares and secure support from directors, executives, and Celadon for the required shareholder approvals.
The most recent analyst rating on (SNTI) stock is a Buy with a $12.00 price target. To see the full list of analyst forecasts on Senti Biosciences stock, see the SNTI Stock Forecast page.
Spark’s Take on SNTI Stock
According to Spark, TipRanks’ AI Analyst, SNTI is a Neutral.
The score is primarily weighed down by weak financial performance: zero recent revenue, substantial ongoing losses and cash burn, and sharply reduced equity driving higher leverage and funding/dilution risk. Technicals offer only modest near-term support (above 20/50-day averages) but remain weak over longer timeframes (below 100/200-day averages). Valuation is constrained by negative earnings (negative P/E) and no dividend yield, while the lease restructuring is a mixed operational step with added near-term financial strain from the letter-of-credit draw.
To see Spark’s full report on SNTI stock, click here.
More about Senti Biosciences
Senti Biosciences Holdings, Inc. operates in the biotechnology sector through its subsidiary Senti Biosciences, Inc., focusing on developing engineered cell and gene therapies, including its product candidate SENTI-202. The company targets advanced therapeutics markets and is aligning its corporate structure, including a holding company reorganization completed on April 24, 2026, to support financing and clinical development efforts.
Average Trading Volume: 165,304
Technical Sentiment Signal: Sell
Current Market Cap: $28.81M
For detailed information about SNTI stock, go to TipRanks’ Stock Analysis page.